Continuous glucose monitoring (CGM) allows for real-time measurement of blood glucose, and is a technology being used by an estimated 7 million individuals in the U.S. and growing. In On the Risk, RGA's Drs. Dave Rengachary and Lauren Garfield explore the ways a sensor placed under the skin can now provide an extremely detailed picture of glucose homeostasis. Underwriters will need to understand the interpretation, associated terminology, limitations, and long-term mortality implications of this monitoring.

In this, the last of our 4-part series of insurance-focused articles on cancer, Dr. Achim Regenauer, Chief Medical Officer, presents a high-level overview of how genomic sequencing of cancers is blasting a trail for improved, early diagnosis and precision medicine by providing a powerful and ever-expanding means to detect, identify, subdivide and monitor cancer – and how this remarkable development could impact Life & Health insurers.

This article is the last in a three-part series, highlighting areas of research funded by the Longer Life Foundation (LLF), a not-for-profit organization that supports the study of scientific and public health factors predicting mortality, morbidity, longevity, and wellness.